/
/
EHA 2020: Ixazomib is Effective as Maintenance for Transplant Ineligible Myeloma Patients
EHA 2020: Ixazomib is Effective as Maintenance for Transplant Ineligible Myeloma Patients image
EHA 2020: Ixazomib is Effective as Maintenance for Transplant Ineligible Myeloma Patients
Posted Jun 18, 2020

Much of the maintenance therapy used in myeloma care includes immunomodulators like Revlimid or Pomalyst, but a presentation from the European Hematology Association 2020 meeting shows that the oral proteasome inhibitor ixazomib (Ninlaro) is an effective maintenance therapy in a placebo-controlled trial. 

Using maintenance therapy after initial treatment can increase the time of remission, but if you become resistant to current classes of drugs, more options are needed.   

The Phase III TOURMALINE-MM4 study compared ixazomib as maintenance vs. a placebo as maintenance for newly diagnosed myeloma patients who were not eligible for a stem cell transplant. The study included 706 patients who received 6-12 months of standard induction (first treatment) myeloma therapy. Seventeen percent of the patients had high risk disease. 

Results were as follows: 

  Ixazomib Placebo
Complete Response (CR) 23% 22%
Very Good Partial Response (VGPR) 40% 40%
Partial Response (PR) 38% 38%
Progression Free Survival (PFS) 17.4 months 9.4 months
PFS of Patients with CR or VGPR 25.6 months 12.9 months
PFS of Patients younger than 75 17.7 months 9.3 months
PFS of Patients older than 75 16.7 months 10.6 months
Time to Progression 17.8 months 9.6 months

 

Dr. Meletios A. Dimopoulos and colleagues noted that using ixazomib as maintenance therapy for patients who are not headed to stem cell transplant provided a meaningful 34% reduction in the risk of myeloma progression or death and had a well-tolerated safety profile. A majority of patients experiences low level grade 1 or 2 side effects, the most common being nausea, vomiting and diarrhea. 

As an oral drug, this may provide another convenient maintenance therapy option and according to Dr. Dimopouolos, may be potentially added with other agents such as immunomodulators and monoclonal antibodies in maintenance therapy combinations. 

 

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811